Spend less to achieve more: Economic analysis of intermittent versus continuous cetuximab in KRAS wild-type patients with metastatic colorectal cancer (2022)
Attributed to:
MICA: Stratification in COloRectal cancer: from biology to Treatment prediction: S-CORT
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.jcpo.2022.100342
PubMed Identifier: 35718327
Publication URI: http://europepmc.org/abstract/MED/35718327
Type: Journal Article/Review
Parent Publication: Journal of Cancer Policy
ISSN: 2213-5383